Biomarker testing in non–small cell lung cancer evolves with new protein-based markers and AI, enhancing personalized treatment strategies for patients.
Kelly King
Advertisement
Articles by Kelly King
The FDA prioritizes Orca-T's review for treating hematologic malignancies, promising improved survival and reduced complications compared with traditional therapies.
Advertisement
Latest Updated Articles
Beyond the Genome: Exploring New Frontiers in NSCLC ManagementPublished: November 17th 2025 | Updated:
Orca-T Earns FDA Priority Review in Heme MalignanciesPublished: October 6th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5
